基础医学与临床 ›› 2008, Vol. 28 ›› Issue (5): 487-491.

• 研究论文 • 上一篇    下一篇

TRAIL及其受体DR5与动脉粥样硬化关系的初步研究

任满意 隋树建 张运 许复郁 马伟红   

  1. 山东大学第二医院心内科 山东大学第二医院心内科 教育部和卫生部心血管重构和功能研究重点实验室 山东大学齐鲁医院心内科 山东大学第二医院病理科 山东大学第二医院心内科
  • 收稿日期:2007-05-10 修回日期:2007-07-09 出版日期:2008-05-25 发布日期:2008-05-25
  • 通讯作者: 隋树建

A premeliary study on the relationship between the plasma levels of TRIAL and DR5 and atherosclerosis

Man-yi REN, Shu-jian SUI, Yun ZHANG, Fu-yu XU, Wei-hong MA   

  1. Second Hospital of Shandong University Second Hospital of Shandong University
  • Received:2007-05-10 Revised:2007-07-09 Online:2008-05-25 Published:2008-05-25
  • Contact: Shu-jian SUI,

摘要: 目的 探讨肿瘤坏死因子相关的凋亡诱导配体(TRAIL)及其受体DR5与动脉粥样硬化(AS)之间的关系。 方法 将83例研究对象分成两组,其中冠心病(CAD)组61例,正常对照组(NCA) 22例。应用酶联免疫吸附法测定所有病例的血浆TRAIL和DR5水平。将20张冠状动脉病理切片分成两组,其中AS和非AS组(nonAS)各10张,免疫组织化学测定TRAIL和DR5蛋白表达情况。 结果 和对照组相比,CAD组血浆TRAIL和DR5水平(1293.30pg/ml±138.17pg/ml vs.333.11 pg/ml±246.15 pg/ml, P=0.000;43.08 pg/ml±16.19 pg/ml vs.34.70pg/ml±13.68 pg/ml, P=0.033)均显著性升高。三支病变组血浆TRAIL和DR5水平显著高于单支病变组和正常对照组,双支病变组也明显高于单支病变组和正常对照组。TRAIL和DR5主要表达于平滑肌细胞的胞浆,TRAIL还可表达于AS中的巨噬细胞。AS组的TRAIL和DR5表达明显高于非AS组(分别为65.48±1.27 vs. 18.66±1.02, P<0.01;60.23±1.09 vs. 30.15±1.16,P<0.05)。 结论 TRAIL可表达于巨噬细胞的胞浆中,TRAIL 及其受体DR5可能参与了AS的发展,其水平的升高在一定程度上反映了CAD的严重程度

关键词: 肿瘤坏死因子相关的凋亡诱导配体, 受体, 动脉粥样硬化, 凋亡, 免疫组织化学

Abstract: Aim:To explore the relationship between the levels of tumor necrosis factor related apoptosis inducing ligand (TRAIL) and death recrptor 5 (DR5) and atherosclerosis(AS). Methods:The 83 patients were divided into two groups: 61 in the coronary artery disease (AS) group and 22 in the nonAS group. Plasma TRAIL and DR5 levels from these people were assayed by ELISA. The 20 sections from coronary arteries were also divided into two groups: 10 in each group. The levels of TRAIL and DR5 protein expression were detected by immunohistochemisty statining. Results:Plasma TRAIL and DR5 levels were significantly increased in the ACS group (1293.30pg/ml±138.17pg/ml vs.333.11 pg/ml±246.15 pg/ml, P=0.000;43.08 pg/ml±16.19 pg/ml vs.34.70pg/ml±13.68 pg/ml, P=0.033). Plasma TRAIL and DR5 levels in patients with 3-vessel involved CAD were significantly higher than those in patients with no- and 1-vessel. So was patients with 2-vessel. Both TRAIL and DR5 were found expressed in endochylema of vascular smooth muscle cell. TRAIL protein expression was also detected in macrophage. There was a markedly higher expression in AS group than nonAS group(65.48±1.27 vs. 18.66±1.02, P<0.01 and 60.23±1.09 vs.30.15±1.16,P<0.05, respectively) Conclusions:TRAIL were expressed in endochylema of macrophage. Both TRAIL and DR5 may contribute to the development of AS. The higher levels of plasma TRAIL and DR5, the greater the degress of coronary arteries lesions would be.

Key words: TNF related apoptosis inducing ligand, receptor, atherosclerosis, apoptosis, immunohistochemistry